Sort by
Refine Your Search
-
The Faculty of Engineering at Université de Sherbrooke has created a competition that fits perfectly with its bold and creative mission. Female doctoral candidates and young doctoral graduates can
-
integrated into current structures, planning, and decision-making modes. Within this hiring process we are committed to creating an inclusive and equitable process for all candidates (including but not limited
-
into current structures, planning, and decision-making modes. Within this hiring process we are committed to creating an inclusive and equitable process for all candidates (including but not limited to people
-
. Potential projects focus on severe ADRs to a range of different medications. Current priority ADRs include cisplatin-induced ototoxicity, anthracycline-induced cardiotoxicity, COVID-19 vaccine-induced
-
on the genetic determinants of severe adverse drug and vaccine reactions. Potential projects focus on severe ADRs to a range of different medications. Current priority ADRs include cisplatin-induced
-
of severe adverse drug and vaccine reactions. Potential projects focus on severe ADRs to a range of different medications. Current priority ADRs include cisplatin-induced ototoxicity, anthracycline-induced
-
applications open in August of each year. These fellowship stipend is currently $7,200 per month for five months, with a travel subsidy for one round-trip from your current institution to the Bay Area, and
-
of its workforce. An inclusive work environment presumes an environment where differences are appreciated, recognized, and integrated into current structures, planning, and decision-making modes. Within
-
of its workforce. An inclusive work environment presumes an environment where differences are appreciated, recognized, and integrated into current structures, planning, and decision-making modes. Within
-
projects with a specific focus on the genetic determinants of severe adverse drug and vaccine reactions. Potential projects focus on severe ADRs to a range of different medications. Current priority ADRs